{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interval+Dosing",
    "query": {
      "intervention": "Interval Dosing"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 314,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interval+Dosing&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T04:32:32.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07416552",
      "title": "A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "SPLIT Abs",
          "type": "DRUG"
        },
        {
          "name": "203Pb-DOTAM",
          "type": "DRUG"
        },
        {
          "name": "212Pb-DOTAM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2026-09-08",
      "completion_date": "2034-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 3,
      "location_summary": "Omaha, Nebraska • Houston, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416552"
    },
    {
      "nct_id": "NCT04889209",
      "title": "Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.211",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.222",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS/M1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 867,
      "start_date": "2021-05-28",
      "completion_date": "2023-06-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 10,
      "location_summary": "Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04889209"
    },
    {
      "nct_id": "NCT04494386",
      "title": "Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "SARS-CoV Infection",
        "ARDS",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Umbilical Cord Lining Stem Cells (ULSC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (carrier control)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Restem, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2020-12-23",
      "completion_date": "2023-05-12",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04494386"
    },
    {
      "nct_id": "NCT03288129",
      "title": "Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Partial Onset Seizures",
        "Secondarily Generalized Seizures",
        "Primary Generalized Tonic-Clonic Seizures"
      ],
      "interventions": [
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-08-23",
      "completion_date": "2021-04-27",
      "has_results": true,
      "last_update_posted_date": "2022-05-16",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288129"
    },
    {
      "nct_id": "NCT00286182",
      "title": "Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Erythropoietin alpha",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mathew S. Maurer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286182"
    },
    {
      "nct_id": "NCT04277546",
      "title": "Open-label Extension Study of Brazikumab in Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Brazikumab Maintenance Dose",
          "type": "DRUG"
        },
        {
          "name": "Brazikumab Induction Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 57,
      "start_date": "2020-03-03",
      "completion_date": "2023-10-10",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 10,
      "location_summary": "Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04277546"
    },
    {
      "nct_id": "NCT02272790",
      "title": "Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2015-01-30",
      "completion_date": "2023-03-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 18,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272790"
    },
    {
      "nct_id": "NCT04610866",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Hemolytic Anemia"
      ],
      "interventions": [
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-09",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04610866"
    },
    {
      "nct_id": "NCT00613132",
      "title": "Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Gleevec, RAD001, and Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2005-05",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613132"
    },
    {
      "nct_id": "NCT07059130",
      "title": "Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Crohn Disease (CD)",
        "Crohns Disease",
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rubix LS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "60 Years to 99 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-07-16",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-09-07T04:32:32.133Z",
      "location_count": 1,
      "location_summary": "Lawrence, Massachusetts",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07059130"
    }
  ]
}